Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection
JH Kim, JL Excler, NL Michael - Annual review of medicine, 2015 - annualreviews.org
RV144 remains the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1
acquisition. The prespecified analysis of immune correlates of risk showed that antibodies …
acquisition. The prespecified analysis of immune correlates of risk showed that antibodies …
[HTML][HTML] Vaccine-induced protection from homologous tier 2 SHIV challenge in nonhuman primates depends on serum-neutralizing antibody titers
MG Pauthner, JP Nkolola, C Havenar-Daughton… - Immunity, 2019 - cell.com
Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from
hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge …
hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge …
Use of adenovirus type-5 vectored vaccines: a cautionary tale
SP Buchbinder, MJ McElrath, C Dieffenbach, L Corey - The Lancet, 2020 - thelancet.com
We are writing to express concern about the use of a recombinant adenovirus type-5 (Ad5)
vector for a COVID-19 phase 1 vaccine study, 1 and subsequent advanced trials. Over a …
vector for a COVID-19 phase 1 vaccine study, 1 and subsequent advanced trials. Over a …
Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity
DE Zak, E Andersen-Nissen… - Proceedings of the …, 2012 - National Acad Sciences
To better understand how innate immune responses to vaccination can lead to lasting
protective immunity, we used a systems approach to define immune signatures in humans …
protective immunity, we used a systems approach to define immune signatures in humans …
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study
GE Gray, Z Moodie, B Metch, PB Gilbert… - The Lancet infectious …, 2014 - thelancet.com
Summary Background The HVTN 503/Phambili study, which assessed the efficacy of the
Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine in South Africa, was stopped …
Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine in South Africa, was stopped …
Newer gene editing technologies toward HIV gene therapy
N Manjunath, G Yi, Y Dang, P Shankar - Viruses, 2013 - mdpi.com
Despite the great success of highly active antiretroviral therapy (HAART) in ameliorating the
course of HIV infection, alternative therapeutic approaches are being pursued because of …
course of HIV infection, alternative therapeutic approaches are being pursued because of …
Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIVmac251 Acquisition in an Immunization Regimen …
The recombinant canarypox vector, ALVAC-HIV, together with human immunodeficiency
virus (HIV) gp120 envelope glycoprotein, has protected 31.2% of Thai individuals from HIV …
virus (HIV) gp120 envelope glycoprotein, has protected 31.2% of Thai individuals from HIV …
Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development
GK Lewis, AL DeVico, RC Gallo - Proceedings of the …, 2014 - National Acad Sciences
The quest for a prophylactic AIDS vaccine is ongoing, but it is now clear that the successful
vaccine must elicit protective antibody responses. Accordingly, intense efforts are underway …
vaccine must elicit protective antibody responses. Accordingly, intense efforts are underway …
Harnessing CD4+ T cell responses in HIV vaccine development
H Streeck, MP D'souza, DR Littman, S Crotty - Nature medicine, 2013 - nature.com
CD4+ T cells can perform a panoply of tasks to shape an effective response against a
pathogen. Limited attention has been paid to the potential importance of functional CD4+ T …
pathogen. Limited attention has been paid to the potential importance of functional CD4+ T …